Affiliation:
1. From the Food and Drug Administration Center for Biologics Evaluation and Research, Bethesda, MD.
Abstract
AbstractWe tested the hypothesis that the antibody response to human factor IX in mice is controlled by genetic factors, especially histocompatibility antigens. Seven inbred mouse strains were immunized against human factor IX by adenoviral gene transfer or serial injections of human factor IX protein. A/J mice had the highest antibody response and 2 C57 mouse strains had the lowest response. We used the adenovirus vector to immunize 26 recombinant inbred mouse strains (AXB and BXA) derived from A/J and C57BL/6J mice and observed highly significant linkage (logarithmic odds [LOD] scores ∼4.8) for the polymorphic D17Mit62 marker that is 1 centimorgan (∼300 000 base pair [bp]) from the mouse major histocompatibility complex (MHC) locus (H-2). Experiments in mice with chimeric MHC genes indicated that class IaK or class II H-2 (or both) genes were critical, but other genes contributed to the antibody response. Polymorphic markers from chromosomes 1 and 10 that are near important immunoregulatory genes such as interleukin 10 and the interferon-γ gene show suggestive linkage (LOD scores of ∼2.3-2.6) to the factor IX antibody response. This study confirms the hypothesis that H-2 (and other) genes control factor IX antibody development in mice and suggests their potential importance for factor IX antibody development in humans with hemophilia B.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference33 articles.
1. Lozier JN, Kessler CM. Clinical aspects and therapy for hemophilia. In: Hoffman R, ed. Hematology, Principles and Practice. New York, NY: Churchill-Livingstone; 1999; 1883-1904.
2. Fulcher CA, de Graaf MS, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood.1987;69: 1475-1480.
3. Kasper CK. Complications of hemophilia A treatment: factor VIII inhibitors. Ann N Y Acad Sci.1991;614: 97-105.
4. Warrier I, Baird-Cox K, Lusher JM. Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience. Haemophilia.1997;3: 194-198.
5. Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood.1997;89: 1115-1116.
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献